Resources

Helpful downloadable resources
In this section, you will find useful resources that you can download to help you support your patients who are prescribed BOSULIF.
HCP resources
Dosing Guide
Dosing Guide
This helpful brochure contains detailed information on dosing, dose modifications, and help managing adverse reactions.
Expert Panel Review: Management of AEs for bosutinib
In 2018, an expert review panel of 7 hematologists discussing how they use BOSULIF as 1L or ≥2L in patients with CP-CML was published in the Journal of Hematology & Oncology. The full article, “Management of Adverse Events Associated With Bosutinib Treatment of Chronic-Phase Chronic Myeloid Leukemia: Expert Panel Review,” can be viewed on the journal site, linked below. A guide highlighting key takeaways is also available here for download. The FDA has not reviewed the recommendations contained in this reprint.
Primary Results From the Phase 4 BYOND Study
In 2020, the primary results of the ongoing, nonrandomized, single-arm, phase 4 BYOND study of BOSULIF in adult patients with chronic or advanced phase Ph+ CML who were resistant/intolerant to prior treatment with TKIs were published in Leukemia. The full article, “Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study,” is available here for download.
Patient resources
Patient Brochure
BOSULIF Patient Brochure
Help your patients start their journey with BOSULIF. Download this brochure, created specifically for patients with CML as a treatment resource, and learn more about what to expect throughout therapy.
AE=adverse event; Ph+=Philadelphia chromosome–positive; TKI=tyrosine kinase inhibitor.
Reference
1.
BOSULIF Prescribing Information. New York, NY: Pfizer Inc.